- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04084795
Augmentation of EMDR With MtCS in the Treatment of Fibromyalgia
Augmentation of EMDR With Multifocal Transcranial Current Stimulation in the Treatment of Fibromyalgia: a Randomized Controlled Trial
Study Overview
Status
Detailed Description
Fibromyalgia (FM) affects 2-4% of the general population with typical symptoms such as generalized and widespread pain, sleep disturbances, problems in memory and attention, anxiety and depression. Pharmacological treatment and psychotherapeutic interventions have produced limited effects so far. Interestingly, lifetime psychosocial adversities are substantially elevated in FM but no interventions are currently offered. Given the complex etiology of FM, combining a psychotherapy with other treatment options can maximize the potential benefit of this intervention. The investigators will test in a marginalized catchment area in Barcelona, whether a trauma-oriented therapy, Eye Movement Desensitization Reprocessing (EMDR), in combination with a non-invasive brain stimulation technique, Multifocal transcranial Current Stimulation (MtCS), can improve typical FM symptoms.
Outcomes
Primary outcomes:
- To test whether EMDR plus MtCS or EMDR plus sham-MtCS in comparison to TAU group, improve pain intensity, depressive and anxious symptoms and trauma associated symptoms after therapy and follow-up.
To test whether an improvement in pain intensity, depressive and anxious symptoms and trauma associated symptoms can be augmented by simultaneous MtCS comparing EMDR plus MtCS with EMDR plus sham-MtCS after the intervention and whether this is maintained at the follow-up visit.
Secondary outcomes:
- To test whether the EMDR plus MtCS or EMDR plus sham-MtCS incomparison to TAU group, improves more in subjective wellbeing after the treatment, and whether this is maintained at the follow-up visit.
Indicators to monitor clinical changes will be performed via various standard self- and hetero-applied scales by blind-to-treatment raters and information provided by patients and the medical chart IT system of our catchment area at baseline (visit 1), post treatment at 6 months (visit 2), and follow-up evaluation at 12 months (visit 3).
This multicenter collaborative project will involve the participation of the Psychiatric Department of the Parc de Salut Mar responsible for coordinating the study, the Rheumatologist Department of the Parc de Salut Mar responsible for patient recruitment, the Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) responsible for randomization and data base management, and the Cognitive Neuro-Lab responsible for the MtCS stimulation.
Design
Within a double-blind randomized controlled design, patients will be randomized to one of the following three treatment arms:
EMDR with MtCS (20 sessions) vs EMDR with sham-MtCS (20 sessions) vs TAU. Psychotherapists, raters, and patients will be kept blind for MtCS treatment conditions until the end of the trial.
Participants
The patient sample will consist of 45 females fulfilling the 2016 American College of Rheumatology criteria for FM based on clinical interview (Wolfe et al, 2010).
Interventions
- EMDR therapy
- Multifocal transcranial Current Stimulation (MtCS)
- Treatment as Usual
Randomizations
The main analysis will be the comparison between patients assigned to EMDR vs not assigned to EMDR, and the secondary analysis will be, among patients assign to EMDR, the comparison between patients with FM assigned to active MtCS vs patients with FM assigned to sham MtCS. Therefore, the investigators will not randomly assign the individuals to one of the three arms but, rather, will randomize patients meeting the inclusion criteria twice: they will first randomize them to EMDR vs non-EMDR, and then will randomize those in the EMDR group to active MtCS or sham MtCS. For the sake of brevity, the investigators describe here only the randomization to EMDR vs non-EMDR, because the randomization to active MtCS vs. sham MtCS is identical. The first two patients will be randomly allocated to EMDR with p=2/3. For each subsequent patient, the following biased coin algorithm will be applied. If a group includes at least two more patients than it would have to have to maintain the ratio 2 EMDR / 1 control, the patient will be randomly assigned to the other group with p=0.6. Otherwise, the researchers will simulate that the new patient is allocated to EMDR and calculate the between-group standardized difference in pain intensity variable, will then simulate that the new patient is allocated to non-EMDR and recalculate the difference, and finally randomly allocate the patient to the group associated to the smallest difference with p=0.6. This strategy decreases prognostic imbalances between groups because it decreases differences in potential confounders but it still includes randomization.
Computation of sample size
The main tests of the study will consist in assessing whether patients assigned to EMDR show different levels of pain intensity variable using standard formula, the total sample size required to detect large to very large effect size differences (Cohen's d ≥ 1) between two groups with a significance level of 0.05 is 13 and 26. Assuming 15% dropouts, the researchers will aim to randomize 45 patients, i.e. 15 and 30 per arm.
Statistical Analysis
The distribution of socio-demographic and clinical characteristics between groups at baseline will be summarized using descriptive statistics. The change in clinical and functional variables from the baseline evaluation to post intervention will be analyzed using linear model t-tests, including as regressors of no interest the potential confounders (age, pain score, anxiety and depression severity, and number of years in education). The statistical software used for the analysis will be the latest available version of R. The investigators will conduct an intention to treat (ITT) analysis, and will use the "Last Observation Carried Forward" (LOCF) method for losses at follow-up.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Catalunya
-
Barcelona, Catalunya, Spain, 08019
- Centre Forum (Parc de Salut Mar)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 18 and 70 years old
- Mean pain score of at least 4 on the visual analog scale (VAS) in the two weeks preceding the clinical trial
- Presence of one or more traumatic events causing current trauma-related symptoms
- Current clinical symptoms of depression and/or anxiety
- 2 weeks of stable medication
Exclusion Criteria:
- Comorbid autoimmune or chronic inflammatory disease
- Neurological or serious medical diseases
- Bipolar disorder, schizoaffective disorder and schizophrenia
- Suicidal ideation
- Previous EMDR therapy
- Substance abuse/dependency within 1 month prior to participation (except for nicotine abuse/dependency),
- Pending FM-related litigation or disability
- Metallic implants in the head
- Positive test for pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: EMDR plus MtCS
MtCS stimulation will consist of 1mA MtDCS for 20 minutes applied immediately before EMDR sessions.
|
EMDR is a psychotherapeutic approach using a standardized 8-phase protocol to alleviate the distress associated with traumatic memories, facilitating the access to and processing of traumatic memories. Patients will receive 20 individual EMDR sessions of 60 minutes each using the standard protocol, as well as a specific pain protocol and the fibromyalgia protocol. EMDR is an integrative psychotherapy that uses standardized protocols and elements of cognitive-behavioral, interpersonal, and body-centered therapies, as well as dual stimulation (e.g., side-to-side eye movements). The current standard protocol includes eight phases: Patient history. Patient preparation. Patient assessment. Memory desensitization. Installing the positive cognition. Body scan. Closure. Reevaluation.
Other Names:
MtCS represents a promising intervention option, given its capacity to modulate cerebral excitability in a simple, safe manner.
F3 anodal; AF3, FC1, FC3, FC5, F5, return montage will be used with the anode over the left DLPFC.
Half of the patients will receive active stimulation and the other half sham stimulation.
Active stimulation will consist of 1mA MtDCS for 20 minutes applied immediately before EMDR sessions.
The same protocol and montage will be used for sham stimulation.
Other Names:
|
PLACEBO_COMPARATOR: EMDR plus sham-MtCS
Sham stimulation will consist of inactive MtDCS for 20 minutes applied immediately before EMDR sessions
|
EMDR is a psychotherapeutic approach using a standardized 8-phase protocol to alleviate the distress associated with traumatic memories, facilitating the access to and processing of traumatic memories. Patients will receive 20 individual EMDR sessions of 60 minutes each using the standard protocol, as well as a specific pain protocol and the fibromyalgia protocol. EMDR is an integrative psychotherapy that uses standardized protocols and elements of cognitive-behavioral, interpersonal, and body-centered therapies, as well as dual stimulation (e.g., side-to-side eye movements). The current standard protocol includes eight phases: Patient history. Patient preparation. Patient assessment. Memory desensitization. Installing the positive cognition. Body scan. Closure. Reevaluation.
Other Names:
|
NO_INTERVENTION: Treatment as Usual
Patients in this condition will not receive EMDR nor MtCS sessions, and will continue to attend their regular visits with rheumatology and psychiatry.
The patients from the TAU group will have the choice to attend 10 sessions of EMDR group therapy when the research project finishes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in pain assessed with the Visual Analogic Scale Questionnaire.
Time Frame: Change from baseline to visits at 6 and 12 months
|
Severity and changes in pain intensity will be assessed with the Visual Analogic Scale (rated in a continuum from 0 to 10).
|
Change from baseline to visits at 6 and 12 months
|
Change in pain assessed with the Pain Dissability Index.
Time Frame: Change from baseline to visits at 6 and 12 months
|
Severity and changes in pain intensity will be assessed with the Pain Disability Index (7 items rated from 0 to 10, making a total score from 0 to 70).
|
Change from baseline to visits at 6 and 12 months
|
Change in pain assessed with the Fibromyalgia Impact Questionnaire.
Time Frame: Change from baseline to visits at 6 and 12 months
|
Severity and changes in pain intensity will be assessed with the Fibromyalgia Impact Questionnaire (the first items is rated from 0 to 4, the second from 0 to 7 and the third from 0 to 5; whereas the other 7 items are rated from 0 to 10, with a cut-off score of 50).
|
Change from baseline to visits at 6 and 12 months
|
Change in depressive symptoms assessed by with the Hospital Anxiety and Depression Scale
Time Frame: Change from baseline to visits at 6 and 12 months
|
Severity and changes in depressive symptoms will be evaluated with the Hospital Anxiety and Depression Scale.
Items are rated on a 4-point Likert scale from 0 and 3, yielding a total score ranging from 0 to 21 and a cut-off score of 8 indicating probable clinical symptoms.
|
Change from baseline to visits at 6 and 12 months
|
Change in anxious symptoms evaluated with the Hospital Anxiety and Depression Scale.
Time Frame: Change from baseline to visits at 6 and 12 months
|
Severity and changes in anxious symptoms will be evaluated with the Hospital Anxiety and Depression Scale.
Items are rated on a 4-point Likert scale from 0 and 3, yielding a total score ranging from 0 to 21 and a cut-off score of 8 indicating probable clinical symptoms.
|
Change from baseline to visits at 6 and 12 months
|
Change in trauma associated symptoms assessed with the Impact of Events Scale-Revised.
Time Frame: Change from baseline to visits at 6 and 12 months
|
Psychological trauma will be evaluated using the Impact of Events Scale-Revised.
This scale consists in 22-item to determine frequency and impact of posttraumatic symptoms experienced, with subscales of intrusion, avoidance and hyperarousal, each scored on a 5-point Likert scale, yielding a score for each subscale and a total score.
This scale has a scoring range of 0 to 88.
On this test, scores that exceed 24 can be quite meaningful.
High scores have the following associations: 24 or more PTSD is a clinical concern.
Those with scores this high who do not have full PTSD will have partial PTSD or at least some of the symptoms; 33 and above represents the best cutoff for a probable diagnosis of PTSD; 37 or more this is high enough to suppress your immune system's functioning (even 10 years after an impact event).
|
Change from baseline to visits at 6 and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in subjective wellbeing measured with the Satisfaction With Life Scale.
Time Frame: Change from baseline to visits at 6 and 12 months
|
The improvement of subjective wellbeing will be evaluated using the Satisfaction With Life Scale.
This scale is completed by 5 items rated from 1 (totally agree) to 5 (totally disagree), with a maximum score of 25.
|
Change from baseline to visits at 6 and 12 months
|
Change in insomnia symptoms assessed with the Athens Insomnia Scale.
Time Frame: Change from baseline to visits at 6 and 12 months
|
The improvement of insomnia symptoms will be evaluated using the Athens Insomnia Scale.
This scale is completed by 8 items rated from 0 to 3, with a maximum score of 24.
|
Change from baseline to visits at 6 and 12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Benedikt L. Amann, M.D., Parc de Salut Mar
Publications and helpful links
General Publications
- Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010 May;62(5):600-10. doi: 10.1002/acr.20140.
- Benor D, Rossiter-Thornton J, Toussaint L. A Randomized, Controlled Trial of Wholistic Hybrid Derived From Eye Movement Desensitization and Reprocessing and Emotional Freedom Technique (WHEE) for Self-Treatment of Pain, Depression, and Anxiety in Chronic Pain Patients. J Evid Based Complementary Altern Med. 2017 Apr;22(2):268-277. doi: 10.1177/2156587216659400. Epub 2016 Jul 20.
- Bernardy K, Klose P, Busch AJ, Choy EH, Hauser W. Cognitive behavioural therapies for fibromyalgia. Cochrane Database Syst Rev. 2013 Sep 10;2013(9):CD009796. doi: 10.1002/14651858.CD009796.pub2.
- Borchers AT, Gershwin ME. Fibromyalgia: A Critical and Comprehensive Review. Clin Rev Allergy Immunol. 2015 Oct;49(2):100-51. doi: 10.1007/s12016-015-8509-4.
- Burke NN, Finn DP, McGuire BE, Roche M. Psychological stress in early life as a predisposing factor for the development of chronic pain: Clinical and preclinical evidence and neurobiological mechanisms. J Neurosci Res. 2017 Jun;95(6):1257-1270. doi: 10.1002/jnr.23802. Epub 2016 Jul 12.
- Cohen H, Neumann L, Haiman Y, Matar MA, Press J, Buskila D. Prevalence of post-traumatic stress disorder in fibromyalgia patients: overlapping syndromes or post-traumatic fibromyalgia syndrome? Semin Arthritis Rheum. 2002 Aug;32(1):38-50. doi: 10.1053/sarh.2002.33719.
- Collado A, Gomez E, Coscolla R, Sunyol R, Sole E, Rivera J, Altarriba E, Carbonell J, Castells X. Work, family and social environment in patients with Fibromyalgia in Spain: an epidemiological study: EPIFFAC study. BMC Health Serv Res. 2014 Nov 11;14:513. doi: 10.1186/s12913-014-0513-5.
- Crettaz B, Marziniak M, Willeke P, Young P, Hellhammer D, Stumpf A, Burgmer M. Stress-induced allodynia--evidence of increased pain sensitivity in healthy humans and patients with chronic pain after experimentally induced psychosocial stress. PLoS One. 2013 Aug 7;8(8):e69460. doi: 10.1371/journal.pone.0069460. eCollection 2013.
- Hampstead BM, Briceno EM, Mascaro N, Mourdoukoutas A, Bikson M. Current Status of Transcranial Direct Current Stimulation in Posttraumatic Stress and Other Anxiety Disorders. Curr Behav Neurosci Rep. 2016 Jun;3(2):95-101. doi: 10.1007/s40473-016-0070-9. Epub 2016 Mar 28.
- Lumley MA, Schubiner H, Lockhart NA, Kidwell KM, Harte SE, Clauw DJ, Williams DA. Emotional awareness and expression therapy, cognitive behavioral therapy, and education for fibromyalgia: a cluster-randomized controlled trial. Pain. 2017 Dec;158(12):2354-2363. doi: 10.1097/j.pain.0000000000001036.
- O'Connell NE, Marston L, Spencer S, DeSouza LH, Wand BM. Non-invasive brain stimulation techniques for chronic pain. Cochrane Database Syst Rev. 2018 Mar 16;3(3):CD008208. doi: 10.1002/14651858.CD008208.pub4.
- Yavne Y, Amital D, Watad A, Tiosano S, Amital H. A systematic review of precipitating physical and psychological traumatic events in the development of fibromyalgia. Semin Arthritis Rheum. 2018 Aug;48(1):121-133. doi: 10.1016/j.semarthrit.2017.12.011. Epub 2018 Jan 10.
- Gardoki-Souto I, Martin de la Torre O, Hogg B, Redolar-Ripoll D, Valiente-Gomez A, Martinez Sadurni L, Blanch JM, Lupo W, Perez V, Radua J, Amann BL, Moreno-Alcazar A. Augmentation of EMDR with multifocal transcranial current stimulation (MtCS) in the treatment of fibromyalgia: study protocol of a double-blind randomized controlled exploratory and pragmatic trial. Trials. 2021 Jan 29;22(1):104. doi: 10.1186/s13063-021-05042-w.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019/8772/I
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibromyalgia
-
University of AberdeenCompletedFibromyalgia | Fibromyalgia, Primary | Fibromyalgia, SecondaryUnited Kingdom
-
Eli Lilly and CompanyCompletedFibromyalgia, Primary | Fibromyalgia, SecondaryMexico
-
Rasmia ElgoharyNot yet recruiting
-
Tel-Aviv Sourasky Medical CenterCompletedFibromyalgia (FM)Israel
-
Yousra Hisham Abdel FattahCompletedFibromyalgia, PrimaryEgypt
-
Forest LaboratoriesCypress Bioscience, Inc.TerminatedPrimary FibromyalgiaUnited States
-
Universidade Federal do Rio Grande do NorteCompleted
-
Tonix Pharmaceuticals, Inc.CompletedPrimary FibromyalgiaUnited States
-
Tonix Pharmaceuticals, Inc.CompletedPrimary FibromyalgiaUnited States
-
University of ManitobaCompleted
Clinical Trials on Eye Movement Desensitization and Reprocessing therapy
-
Istanbul Sehir UniversityUnknown
-
University Hospital HeidelbergCompletedNon-specific Chronic Back PainGermany
-
Parc de Salut MarFundacion IMIM; EMDR EuropeCompletedPsychological Trauma | Severe Mental DisorderSpain
-
Norwegian University of Science and TechnologySt. Olavs HospitalWithdrawnSpecific Phobia
-
Miao-Yi ChenCompletedAnxiety | Blood Pressure | Heart Rate Variability | Eye Movement Desensitization and Reprocessing InterventionTaiwan
-
University of SalfordCompletedTrauma, PsychologicalUnited Kingdom
-
University Hospital MuensterCompleted
-
FIDMAG Germanes HospitalàriesCompletedPTSD | Bipolar DisorderSpain
-
University of Turin, ItalyEMDR EuropeRecruitingDepression | Heart Rate Variability | Functional Magnetic Resonance Imaging | Cognitive Behavioral Therapy | Eye Movement Desensitization and Reprocessing | Neurobiological Processing | High Definition ElectroencefalographyItaly
-
Fondazione Don Carlo Gnocchi OnlusCatholic University of the Sacred Heart; EMDR EuropeNot yet recruitingDepression | Multiple Sclerosis